SYRE vs TRAX
SYRE: Spyre Therapeutics is developing next-generation, extended half-life antibodies and combination therapies aimed at redefining the standard of care for inflammatory bowel disease and immune-mediated conditions. TRAX: Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.
Side-by-side fundamentals
| Metric | SYRE | TRAX | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $105.33 | $45.33 | |
| Market cap as of 2026-08-11 | $9.3B | $1.6B | |
| Net margin as of 2026-08-11 | -22158.5% | n/a | |
| Operating margin as of 2026-08-11 | -17559.3% | n/a | |
| ROE as of 2026-08-11 | -24.3% | -57.8% | SYRE higher |
| ROA as of 2026-08-11 | -22.2% | -50.2% | SYRE higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-11 | 3.07 | 1.14 | |
| 1-year return as of 2026-08-10 close | +594.8% | n/a |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.